Kim Si-Wook, Choi Moon Ki, Han Hye Sook, Song Hyojin, Koh Youngil, Son Seung-Myoung, Lee Ok-Jun, Lee Ji Yeoun, Lee Ki Man, Lee Ki Hyeong, Kwon Jihyun
Department of Thoracic and Cardiovascular Surgery, Chungbuk National University College of Medicine, Cheongju, Republic of Korea.
Acta Haematol. 2017;138(1):24-30. doi: 10.1159/000476026. Epub 2017 Jun 15.
Langerhans cell histiocytosis (LCH) and Langerhans cell sarcoma (LCS) are clonal proliferations of Langerhans-type cells. Unlike in LCH, the pathophysiology and clinical course of LCS are unclear due to its rarity. Here, we report the case of a 73-year-old male patient who was diagnosed with cutaneous LCH and pulmonary LCS at the same time. Pathological review of these 2 tumors revealed similar immunohistochemical findings. However, the tumor cells in LCS had more aggressive cytological features than those in LCH. Results of BRAF mutation analysis using real-time PCR were negative for both tumors. In whole-exome sequencing (WES), stop-gain mutations in TP53 gene were discovered only in LCS cells. The mechanism of development of LCS from various progenitor cells is currently unclear. According to the results of the WES study, changes in TP53 gene might have contributed to the malignant features of LCS.
朗格汉斯细胞组织细胞增多症(LCH)和朗格汉斯细胞肉瘤(LCS)是朗格汉斯型细胞的克隆性增殖。与LCH不同,由于LCS罕见,其病理生理学和临床病程尚不清楚。在此,我们报告一例73岁男性患者,其同时被诊断为皮肤LCH和肺LCS。对这两种肿瘤的病理检查显示出相似的免疫组化结果。然而,LCS中的肿瘤细胞比LCH中的具有更具侵袭性的细胞学特征。使用实时PCR进行的BRAF突变分析结果显示两种肿瘤均为阴性。在全外显子测序(WES)中,仅在LCS细胞中发现了TP53基因的终止密码子获得性突变。目前尚不清楚LCS从各种祖细胞发展而来的机制。根据WES研究结果,TP53基因的变化可能促成了LCS的恶性特征。